Related content

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus

By Swen Jesse J   Wessels Judith AM   Krabben Annemarie   Assendelft Willem JJ   Guchelaar Henk-Jan  

Pharmacogenomics, Vol. 11, Iss. 11, 2010-11 ,pp. : 1517-1523

Future Medicine

Access to resources Recommend Favorite

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele

By Andersson Marine L   Eliasson Erik   Lindh Jonatan D  

Pharmacogenomics, Vol. 13, Iss. 7, 2012-05 ,pp. : 757-762

Future Medicine

Access to resources Recommend Favorite

Allele Frequency Distributions of the Drug Metabolizer Genes CYP2C9*2, CYP2C9*3, and CYP2C19*17 in the Buginese Population of Indonesia

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 12, Iss. 4, 2014-12 ,pp. : 236-239

Bentham Science Publishers

Access to resources Recommend Favorite

The role of sulfonylureas in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1301, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes

By Holstein Judith Dina   Kovacs Peter   Patzer Olaf   Stumvoll Michael   Holstein Andreas  

Pharmacogenomics, Vol. 13, Iss. 1, 2012-01 ,pp. : 5-7

Future Medicine

Access to resources Recommend Favorite